GlassScriptPhysician profile
Lester Tsai
NPI 1770080541
$1,797.37
in general payments reported to CMS, 2019-2025
11 companies · $385 in 2025
The $385 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.00 · 2023: $963 · 2024: $400 · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,747.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $421.84 | 2022-2025 | Livdelzi, Epclusa, Vemlidy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.06 | 2023-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $191.25 | 2023 | Zeposia |
| Boston Scientific Corporation | $181.38 | 2023-2024 | Exalt Model D |
| Madrigal Pharmaceuticals | $171.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Perspectum Diagnostics LTD | $144.32 | 2023 | Livermultiscan |
| Janssen Pharmaceuticals, INC | $135.98 | 2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $120.85 | 2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $98.46 | 2024 | |
| Olympus America INC. | $50.02 | 2023-2024 | Disposable Biopsy Forceps, Gastrointestinal Videoscope |
| Abbvie INC. | $33.74 | 2023 | Linzess |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lester Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.